Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Not Confirmed
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Not Confirmed
Not Confirmed
28 October-01 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Saudi International Ex...Saudi International Expo
Industry Trade Show
Not Confirmed
28-30 October, 2024
SupplySide West 2024SupplySide West 2024
Industry Trade Show
Not Confirmed
28 October-01 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
08 Apr 2024
// Julie Steenhuysen REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/geneos-cancer-vaccine-shrinks-liver-tumors-small-trial-2024-04-07/
07 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/geneos-therapeutics-announces-positive-phase-12-data-for-gt-30-trial-of-personalized-therapeutic-cancer-vaccine-302109588.html
27 Sep 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/geneos-therapeutics-closes-its-series-a3-financing-with-investment-of-5-million-301941077.html
28 Jul 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/geneos-therapeutics-nominated-for-2023-prix-galien-usa-startup-award-301887990.html
12 Apr 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/geneos-therapeutics-secures-5-million-in-series-a3-financing-301795107.html
24 Mar 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/geneos-therapeutics-secures-17-million-in-series-a2-financing-to-advance-personalized-cancer-immunotherapy-platform-301509602.html
Details:
GNOS-PV02 combines DNA plasmid PTCV, IL-12, and pembrolizumab for advanced hepatocellular carcinoma after multi-tyrosine kinase treatment.
Lead Product(s): GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Brand Name: GNOS-PV02
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Lead Product(s) : GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Cancer Vaccine Trial
Details : GNOS-PV02 combines DNA plasmid PTCV, IL-12, and pembrolizumab for advanced hepatocellular carcinoma after multi-tyrosine kinase treatment.
Brand Name : GNOS-PV02
Molecule Type : Vaccine
Upfront Cash : Not Applicable
April 07, 2024
Details:
The net proceeds will fund completion of phase 1b/2a GT-30 Program evaluating personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with Pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcinoma.
Lead Product(s): GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Brand Name: GNOS-PV02
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Shanghai Healthcare Capital
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 27, 2023
Lead Product(s) : GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Shanghai Healthcare Capital
Deal Size : $10.0 million
Deal Type : Series A Financing
Geneos Therapeutics Closes its Series A3 Financing with Investment of $5 Million
Details : The net proceeds will fund completion of phase 1b/2a GT-30 Program evaluating personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with Pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcin...
Brand Name : GNOS-PV02
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 27, 2023
Details:
The net proceeds will fund expansion of Phase 1b/2a GT-30 Program. GT-30 is evaluating safety, immunogenicity, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) in patients with unresectable or metastatic HCC.
Lead Product(s): GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Brand Name: GNOS-PV02
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: 3B Future Health Fund
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 12, 2023
Lead Product(s) : GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : 3B Future Health Fund
Deal Size : $5.0 million
Deal Type : Series A Financing
Geneos Therapeutics Secures $5 Million in Series A3 Financing
Details : The net proceeds will fund expansion of Phase 1b/2a GT-30 Program. GT-30 is evaluating safety, immunogenicity, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) in patients with unresectable or metastatic HCC.
Brand Name : GNOS-PV02
Molecule Type : Vaccine
Upfront Cash : Undisclosed
April 12, 2023
Details:
The proceeds will be used for the expansion of the company’s GT-30 Phase Ib/IIa clinical trial. GT-30 evaluates Geneos’ personalized cancer vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer.
Lead Product(s): GT-30,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Brand Name: GNOS-PV02
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Sante Ventures
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 24, 2022
Lead Product(s) : GT-30,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Sante Ventures
Deal Size : $17.0 million
Deal Type : Series A Financing
Details : The proceeds will be used for the expansion of the company’s GT-30 Phase Ib/IIa clinical trial. GT-30 evaluates Geneos’ personalized cancer vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer...
Brand Name : GNOS-PV02
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 24, 2022
Details:
Geneos Therapeutics, Inc. has executed a new purchasing contract under their current Clinical Manufacturing Supply Agreement to support the expansion of the ongoing clinical trial for GNOS-PV02.
Lead Product(s): GT-30,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Brand Name: GNOS-PV02
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Recipient: VGXI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 16, 2021
Lead Product(s) : GT-30,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : VGXI
Deal Size : Undisclosed
Deal Type : Partnership
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Details : Geneos Therapeutics, Inc. has executed a new purchasing contract under their current Clinical Manufacturing Supply Agreement to support the expansion of the ongoing clinical trial for GNOS-PV02.
Brand Name : GNOS-PV02
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 16, 2021
Details:
Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
Lead Product(s): GNOS-PV02,Pembrolizumab,INO-9012
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
Lead Product(s) : GNOS-PV02,Pembrolizumab,INO-9012
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 29, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?